Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): disparities between younger and older patients
A partir des données du registre néerlandais des cancers portant sur 187 315 patients atteints d'un cancer du poumon non à petites cellules sur la période 1990-2014, cette étude analyse l'évolution des traitements et de la survie relative, en fonction de l'âge des patients (inférieur ou supérieur à 70 ans)
Background : This study aimed to describe trends over time regarding disparities in treatment and relative survival (RS) between younger and older patients with non-small cell lung cancer (NSCLC). Methods : All patients diagnosed with pathologically verified NSCLC in 1990-2014 were included from the Netherlands Cancer Registry (n = 187,315). Treatment and RS (adjusted for sex, histology, treatment) were analyzed according to age group (<70 years versus ≥70 years), stage, and 5-year period of diagnosis. Results : Between 1990 and 2014, 5-year RS increased from 17% to 22% among younger patients and from 12% to 16% among elderly. The application of surgery increased over time for elderly with stage I NSCLC, decreased for elderly with stage II, and was stable but higher for younger patients. Disparities in RS between age groups with stage I became smaller since 2000-2004, but did not change over time for stage II. For stage III and IV, both age groups showed strong increases over time in chemoradiotherapy and chemotherapy from 2000 onwards, although considerably less among elderly. One-, 3- and 5-year RS increased more strongly over time for the younger group leading to larger disparities between age groups with stage III or IV NSCLC. Conclusion : More curative-intent treatment and improved RS for NSCLC were seen over time, but were less profound among elderly. Disparities herein between age groups seemed to become smaller over time for stage I NSCLC, did not change for stage II, and were widening for stage III and IV at the expense of elderly. Future prospective studies should focus on optimizing treatment selection and outcomes for elderly